Sector News

Under-pressure Biogen aims to please restive investors with bigger, better board

April 30, 2019
Life sciences

Biogen knows what it’s like to confront rebellious investors. Ten years ago, it faced a proxy fight with activist Carl Icahn that ended with two new directors on its board.

So in a way, it’s no surprise that the biotech’s Alzheimer’s drug flop last month—and the spectacular drop in market cap that followed—prompted Biogen to add three new members to its board.

Chairman Stelios Papadopoulos said Biogen “heard the calls from our shareholders” and plans to expand its board to bring in new blood and new expertise. The board will grow to 14 seats from 11, with three nominees up for a vote in June: Catalent CEO John Chiminski, ex-Medtronic CEO William Hawkins and IBM exec Jesus Mantas.

The three new board members would help Biogen pick up the pieces after its aducanumab trial failure, which wiped about 30% off of the company’s market capitalization. Facing a barrage of analyst questions on the company’s Q1 earnings call last week, CEO Michel Vounastos said the company has the “opportunity and obligation” to rebound from that setback.

To appease investors in the meantime, the company rolled out $5 billion in new stock buybacks, Vounatsos promised he’d keep scouting for potential pipeline-building deals.

On Monday, Vounatsos said the new board nominees have “diverse backgrounds and experience in scientific, medical, and digital innovation” that are “highly complementary to our pioneering vision.”

Chiminski is board chair and CEO of Catalent, the contract research and biopharma services company. Hawkins is a senior advisor at the life sciences private equity firm EW Healthcare Partners, but before that, he led the medtech company Medtronic. Mantas is managing partner and general manager at IBM Global Business Services, which helps companies weave digital into their operations.

Alex Denner, the activist investor who first joined Biogen’s board after that 2009 proxy fight, said in a statement he’s “excited” about the appointments. Denner chairs Biogen’s corporate governance committee.

“Today’s announcement is a significant step in the board’s refreshment, and we will continue the process with a view toward further diversifying and enhancing the makeup of the board,” Denner added.

If Biogen amps up its digital ambitions after the aducanumab flop, as the nominations suggest it will, the company certainly wouldn’t be the first biopharma company to do so. Novartis CEO Vas Narasimhan and his predecessor Joe Jimenez both pointed to digital as a top goal, and the Swiss drugmaker now boasts its first chief digital officer in Bertrand Bodson. And Pfizer, Merck & Co. and GlaxoSmithKline have all recruited their first chief digital officers over the past couple of years.

Biogen executives said on last week’s first-quarter conference call the company plans to keep advancing its pipeline and scouting new drug candidates following its Alzheimer’s setback. The company now focuses on multiple sclerosis, SMA and biosims, but it’s planning to advance into ophthalmology, movement disorders, neuromuscular diseases, stroke and more in the 2020s, they said. The drugmaker still has ambitions in pain, Alzheimer’s and neurocognitive disorders as well.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach